AC Immune Reports Early Phase 1 Progress for Brain-Penetrant NLRP3 Inhibitor ACI-19764

Key Points

• ACI-19764 is an oral small-molecule drug designed to inhibit the NLRP3 inflammasome, an immune pathway associated with inflammation.
• Preliminary single-ascending-dose and multiple-ascending-dose data showed no serious adverse events or treatment discontinuations through the reported period.
• Doses of 10 mg or less once daily achieved drug concentrations above AC Immune’s IC90 target, the level associated with 90% target inhibition in its assay.
• The drug was detected in cerebrospinal fluid, suggesting that it enters the central nervous system.
• Whole-blood testing showed dose-dependent inhibition of IL-1β release, an early biomarker of NLRP3 pathway activity.
• AC Immune has begun dosing a Phase 1b cohort of participants with elevated inflammation markers and metabolic risk factors.

AC Immune SA (Nasdaq: ACIU) reported preliminary Phase 1 results showing that ACI-19764, its oral NLRP3 inhibitor, was safe and well tolerated in healthy participants to date. The company also reported early evidence that the drug reaches the central nervous system and affects its intended inflammatory pathway.

 Phase 1 Study Evaluates Safety and Early Drug Activity

The first-in-human Phase 1 study is evaluating ACI-19764 in healthy participants through single- and multiple-ascending-dose cohorts. Researchers are assessing safety, tolerability, pharmacokinetics, and pharmacodynamics, which measure how the drug moves through the body and affects its biological target.

The current findings are preliminary. They come from healthy volunteers rather than people with Alzheimer’s disease, Parkinson’s disease, or other neurodegenerative conditions. As a result, the data do not demonstrate that ACI-19764 can improve symptoms, slow disease progression, or provide a clinical benefit.

Brain Exposure Supports AC Immune’s Neuroinflammation Strategy

AC Immune reported measurable ACI-19764 levels in cerebrospinal fluid, or CSF. Because CSF surrounds the brain and spinal cord, this finding provides early evidence that the compound crosses into the central nervous system.

The company also reported a serum half-life exceeding 30 hours. Based on the early pharmacokinetic data, AC Immune believes a dose of 10 mg or less once daily could maintain drug exposure above its IC90 target.

If confirmed in further trials, these results may support a once-daily oral treatment approach. However, brain penetration and target drug levels do not establish a safe long-term dose or prove that the drug will work in patients.

IL-1β Inhibition Shows Early NLRP3 Target Engagement

In blinded whole-blood testing, ACI-19764 produced dose-dependent inhibition of IL-1β release after laboratory stimulation. IL-1β is a pro-inflammatory signaling protein released downstream of NLRP3 inflammasome activation.

The result offers preliminary evidence of target engagement. In other words, the drug appears to affect the inflammatory pathway it was designed to inhibit. This is a useful early development signal, but it is not evidence of clinical efficacy or disease modification.

Phase 1b Cohort Adds a Systemic Inflammation Readout

AC Immune has begun the Phase 1b portion of the program in adults with elevated high-sensitivity C-reactive protein, or hsCRP, plus type 2 diabetes and/or obesity. hsCRP is a blood marker used to assess systemic inflammation.

The Phase 1b cohort will help evaluate safety and changes in inflammation-related biomarkers in a group with elevated cardiovascular and metabolic risk. AC Immune expects preliminary Phase 1b data by the end of 2026 and full Phase 1/1b results in the first half of 2027.

Next Data Will Shape the ACI-19764 Investment Case

The early data address several key questions around oral administration, safety to date, central nervous system exposure, and NLRP3 pathway activity. The program remains at an early stage and carries significant clinical and regulatory risk.

For ACIU investors, the next milestones include Phase 1b hsCRP results, the full Phase 1/1b safety and pharmacokinetic dataset, dose-selection updates, patient-trial plans, and the company’s financing needs. ACI-19764 is not approved for any indication, and its value will depend on whether these early findings lead to meaningful results in future patient studies.